Section Arrow
Quote
ANEB.NASDAQ
- Anebulo Pharmaceuticals
Quotes are at least 15-min delayed:2025/06/02 15:21 EDT
Last
 1.0124
-0.032 (-3.06%)
Day High 
1.0699 
Prev. Close
1.0444 
1-M High
1.3 
Volume 
2.83K 
Bid
1.02
Ask
1.06
Day Low
1.0124 
Open
1.0418 
1-M Low
0.97 
Market Cap 
42.91M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.07 
20-SMA 1.06 
50-SMA 1.13 
52-W High 3.08 
52-W Low 0.8001 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.25/-0.48
Enterprise Value
42.91M
Balance Sheet
Book Value Per Share
0.33
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
OGENOragenics0.1718+0.0518+43.17%-- 
PSTVPlus Therapeutics0.3949+0.108+37.64%-- 
PCSAProcessa Pharmaceuticals0.2979+0.0054+1.85%-- 
BPMCBlueprint Medicines Corp127.58+26.23+25.88%-- 
NCNANuCana plc0.0374+0.0021+5.95%-- 
Quotes are at least 15-min delayed：2025/06/02 15:21 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.